Cobimetinib Prices, Discounts & Coupons

Cobimetinib is available as a 20 mg oral tablet.

Cobimetinib is a MEK inhibitor that is used to treat:

• Melanoma with certain BRAF mutations that has spread (metastatic) or can’t be removed by surgery, used together with Zelboraf (vemurafenib)
• Histiocytic neoplasms

Cobimetinib is a kinase inhibitor known as a MEK inhibitor. MEK is a protein in the body that’s important for cell growth. Cobimetinib works by blocking the MEK protein. When the medication blocks MEK, cancer cells can’t grow and spread as well. For people with melanoma with a BRAF mutation, Cobimetinib is taken with Zelboraf (vemurafenib). The BRAF protein also helps cells grow, and cells can grow too quickly when there’s a BRAF mutation. By blocking two different proteins, Cobimetinib and vemurafenib (Zelboraf) work together to stop the growth and spread of cancer better.

The usual dose is 60 mg by mouth once a day for 3 weeks. Then, you’ll take 1 week off from the medication. This is considered one treatment cycle. Repeat the treatment cycle (3 weeks of treatment, followed by 1 week off) for as long as you’re taking the medication.

Cobimetinib is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Cobimetinib:

• Higher creatinine levels in blood
• Higher liver enzymes in blood
• Higher creatine phosphokinase (CPK) levels in blood
• Other blood test abnormalities
• Diarrhea
• Skin that’s sensitive to the sun
• Nausea
• Fever
• Vomiting

Serious side effects are rare with Cobimetinib. Contact your healthcare provider immediately if you experience any of the following.

• Bleeding: blood in urine, blood in stool, vaginal bleeding, sudden and severe headache
• Serious eye problems: sudden and severe eye pain, sudden vision loss
• Serious muscle problems: severe muscle pain or stiffness, dark red or brown urine, sudden muscle weakness

The following medications may interact with Cobimetinib:

• Avoid concomitant administration of Cobimetinib with strong or moderate CYP3A inducers or inhibitors

Various FDA-approved generic manufacturers

Cobimetinib can harm your unborn baby. Females who are able to become pregnant should use effective birth control (contraception) during treatment with Cobimetinib and for 2 weeks after the final dose of Cobimetinib.
Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with Cobimetinib.

• Cotellic